BioCentury | Nov 10, 2020
Finance

RemeGen’s value surpasses $4B after pricing 2020’s largest biotech IPO

...Co. Ltd. was founded in 2008 by CEO and CSO Jianmin Fang, a professor of molecular medicine...
BioCentury | Aug 6, 2020
Emerging Company Profile

T-knife: creating TCR factories with transgenic mice

...generate human, high affinity TCRs. The Berlin-based company spun out of the Max-Delbrück Center for Molecular Medicine...
...Germany Technology: Humanized TCRs derived from transgenic mouse platform Origin of technology: Max-Delbrück Center for Molecular Medicine...
...I Founded: 2018 by Elisa Kieback, Thomas Blankenstein, Holger Specht University collaborators: Max-Delbrück Center for Molecular Medicine...
BioCentury | Apr 15, 2020
Product Development

Let’s improve molecular diagnostics reimbursement for the sake of public health

...national system of molecular diagnostic instruments, with networked reporting, to enable the widespread practice of molecular medicine...
...local level. We have not offered proper financial incentives for community hospitals to invest in molecular medicine...
...and a risk-adjusted payment system for PD1 inhibitors in cancer. I think better reimbursement for molecular medicine...
BioCentury | Apr 8, 2020
Finance

Suzhou Ribo raises $66.3M for nucleic acid therapies

...2007 by Chairman Zicai Liang, an siRNA researcher and professor at Peking University Institute of Molecular Medicine...
BioCentury | Apr 4, 2020
Finance

Megarounds for Chinese biopharmas Legend, RemeGen to support late-stage push

...Co. Ltd. was founded in 2008 by CEO and CSO Jianmin Fang, a professor of molecular medicine...
BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

...of St. Jude in the infectious diseases department -- was described in 2013 in EMBO Molecular Medicine...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

...but the details are far from worked out," James Paulson, a professor of chemistry and molecular medicine...
BioCentury | Nov 15, 2019
Financial News

Atomwise JV raises $14.5M series A to advance AI-discovered candidates

...James Larrick and Andrew Perlman serve as Velocity’s CMO. Larrick founded incubator Panorama Institute of Molecular Medicine...
BioCentury | Oct 15, 2019
Emerging Company Profile

Abalos’ arena: planning to upstage oncolytic viruses

...immunology at the University of Duisburg-Essen, and Philipp Lang is director of the Department of Molecular Medicine...
BioCentury | Aug 30, 2019
Translation in Brief

DNA trumps protein in Huntington onset

...coauthor Hayden, who is director and senior scientist at University of British Columbia's Centre for Molecular Medicine...
Items per page:
1 - 10 of 267
BioCentury | Nov 10, 2020
Finance

RemeGen’s value surpasses $4B after pricing 2020’s largest biotech IPO

...Co. Ltd. was founded in 2008 by CEO and CSO Jianmin Fang, a professor of molecular medicine...
BioCentury | Aug 6, 2020
Emerging Company Profile

T-knife: creating TCR factories with transgenic mice

...generate human, high affinity TCRs. The Berlin-based company spun out of the Max-Delbrück Center for Molecular Medicine...
...Germany Technology: Humanized TCRs derived from transgenic mouse platform Origin of technology: Max-Delbrück Center for Molecular Medicine...
...I Founded: 2018 by Elisa Kieback, Thomas Blankenstein, Holger Specht University collaborators: Max-Delbrück Center for Molecular Medicine...
BioCentury | Apr 15, 2020
Product Development

Let’s improve molecular diagnostics reimbursement for the sake of public health

...national system of molecular diagnostic instruments, with networked reporting, to enable the widespread practice of molecular medicine...
...local level. We have not offered proper financial incentives for community hospitals to invest in molecular medicine...
...and a risk-adjusted payment system for PD1 inhibitors in cancer. I think better reimbursement for molecular medicine...
BioCentury | Apr 8, 2020
Finance

Suzhou Ribo raises $66.3M for nucleic acid therapies

...2007 by Chairman Zicai Liang, an siRNA researcher and professor at Peking University Institute of Molecular Medicine...
BioCentury | Apr 4, 2020
Finance

Megarounds for Chinese biopharmas Legend, RemeGen to support late-stage push

...Co. Ltd. was founded in 2008 by CEO and CSO Jianmin Fang, a professor of molecular medicine...
BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

...of St. Jude in the infectious diseases department -- was described in 2013 in EMBO Molecular Medicine...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

...but the details are far from worked out," James Paulson, a professor of chemistry and molecular medicine...
BioCentury | Nov 15, 2019
Financial News

Atomwise JV raises $14.5M series A to advance AI-discovered candidates

...James Larrick and Andrew Perlman serve as Velocity’s CMO. Larrick founded incubator Panorama Institute of Molecular Medicine...
BioCentury | Oct 15, 2019
Emerging Company Profile

Abalos’ arena: planning to upstage oncolytic viruses

...immunology at the University of Duisburg-Essen, and Philipp Lang is director of the Department of Molecular Medicine...
BioCentury | Aug 30, 2019
Translation in Brief

DNA trumps protein in Huntington onset

...coauthor Hayden, who is director and senior scientist at University of British Columbia's Centre for Molecular Medicine...
Items per page:
1 - 10 of 267